ODU Digital Commons
metadata only
Nirmatrelvir-Ritonavir Targeting Viral Persistence in Post-COVID-19 Condition (Long Covid) in the USA (RECOVER-VITAL): A Randomized, Double-Blind, Placebo Controlled, Phase 2 Trial
Background Post-acute sequelae of SARS-CoV-2 infection, more commonly known as long COVID, has emerged as a major health problem. The pathogenesis of long COVID is unknown, but among the leading hypotheses is viral persistence. We aimed to investigate whether the use of the SARS-CoV-2 antiviral nirm
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Host Factors Modulate Nirmatrelvir-Ritonavir Efficacy in COVID-19 Patients: A Viral Dynamics Modeling Study#152654
- Prophylaxis and Treatment of COVID-19#1186000
- Real World COVID-19 Antiviral Effectiveness Research#830601
- ImPROving Quality of LIFe in the Long COVID Patient#1113439
- Oral nirmatrelvir-ritonavir for COVID-19 in higher risk outpatients#298976
Record · ID 1404561
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive